vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与Purple Innovation, Inc.（PRPL）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是Purple Innovation, Inc.的1.1倍（$152.6M vs $140.7M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs -2.3%，领先36.8%），Purple Innovation, Inc.同比增速更快（9.1% vs 7.6%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $-7.8M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 8.3%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
Purple Carrot是一家总部位于马萨诸塞州尼达姆市的全植物性餐包品牌，由安迪·莱维特创立，每周为订阅用户提供预制餐品和自制餐包。据《大都会》2022年报道，对比美式标准餐食，该品牌每份餐包的碳排放量可降低72%，主打低碳环保的纯植物饮食方案。
CPRX vs PRPL — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $140.7M |
| 净利润 | $52.7M | $-3.2M |
| 毛利率 | 82.9% | 41.9% |
| 营业利润率 | 40.5% | -1.6% |
| 净利率 | 34.5% | -2.3% |
| 营收同比 | 7.6% | 9.1% |
| 净利润同比 | -5.8% | 62.1% |
| 每股收益（稀释后） | $0.40 | $0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $140.7M | ||
| Q3 25 | $148.4M | $118.8M | ||
| Q2 25 | $146.6M | $105.1M | ||
| Q1 25 | $141.4M | $104.2M | ||
| Q4 24 | $141.8M | $129.0M | ||
| Q3 24 | $128.7M | $118.6M | ||
| Q2 24 | $122.7M | $120.3M | ||
| Q1 24 | $98.5M | $120.0M |
| Q4 25 | $52.7M | $-3.2M | ||
| Q3 25 | $52.8M | $-11.7M | ||
| Q2 25 | $52.1M | $-17.3M | ||
| Q1 25 | $56.7M | $-19.1M | ||
| Q4 24 | $55.9M | $-8.5M | ||
| Q3 24 | $43.9M | $-39.2M | ||
| Q2 24 | $40.8M | $27.0K | ||
| Q1 24 | $23.3M | $-50.2M |
| Q4 25 | 82.9% | 41.9% | ||
| Q3 25 | 84.7% | 42.8% | ||
| Q2 25 | 85.9% | 35.9% | ||
| Q1 25 | 87.3% | 39.4% | ||
| Q4 24 | 84.7% | 42.9% | ||
| Q3 24 | 85.0% | 29.7% | ||
| Q2 24 | 87.4% | 40.7% | ||
| Q1 24 | 87.3% | 34.8% |
| Q4 25 | 40.5% | -1.6% | ||
| Q3 25 | 44.7% | -10.2% | ||
| Q2 25 | 45.2% | -13.5% | ||
| Q1 25 | 44.8% | -13.9% | ||
| Q4 24 | 44.3% | -6.0% | ||
| Q3 24 | 39.6% | -39.5% | ||
| Q2 24 | 44.2% | -12.1% | ||
| Q1 24 | 27.5% | -19.3% |
| Q4 25 | 34.5% | -2.3% | ||
| Q3 25 | 35.6% | -9.9% | ||
| Q2 25 | 35.6% | -16.5% | ||
| Q1 25 | 40.1% | -18.4% | ||
| Q4 24 | 39.4% | -6.6% | ||
| Q3 24 | 34.1% | -33.1% | ||
| Q2 24 | 33.2% | 0.0% | ||
| Q1 24 | 23.6% | -41.8% |
| Q4 25 | $0.40 | $0.03 | ||
| Q3 25 | $0.42 | $0.11 | ||
| Q2 25 | $0.41 | $0.16 | ||
| Q1 25 | $0.45 | $0.18 | ||
| Q4 24 | $0.44 | $0.08 | ||
| Q3 24 | $0.35 | $0.36 | ||
| Q2 24 | $0.33 | $0.00 | ||
| Q1 24 | $0.19 | $0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $24.3M |
| 总债务越低越好 | — | $126.7M |
| 股东权益账面价值 | $954.3M | $-29.7M |
| 总资产 | $1.1B | $296.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $24.3M | ||
| Q3 25 | $689.9M | $32.4M | ||
| Q2 25 | $652.8M | $34.2M | ||
| Q1 25 | $580.7M | $21.6M | ||
| Q4 24 | $517.6M | $29.0M | ||
| Q3 24 | $442.3M | $23.4M | ||
| Q2 24 | $375.7M | $23.4M | ||
| Q1 24 | $310.4M | $34.5M |
| Q4 25 | — | $126.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $70.7M | ||
| Q3 24 | — | $50.8M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $954.3M | $-29.7M | ||
| Q3 25 | $920.2M | $-26.9M | ||
| Q2 25 | $856.0M | $-15.6M | ||
| Q1 25 | $794.3M | $1.3M | ||
| Q4 24 | $727.6M | $20.2M | ||
| Q3 24 | $660.9M | $28.0M | ||
| Q2 24 | $608.7M | $66.4M | ||
| Q1 24 | $561.4M | $65.5M |
| Q4 25 | $1.1B | $296.3M | ||
| Q3 25 | $1.1B | $302.1M | ||
| Q2 25 | $971.9M | $303.8M | ||
| Q1 25 | $908.9M | $293.8M | ||
| Q4 24 | $851.4M | $307.8M | ||
| Q3 24 | $772.0M | $309.3M | ||
| Q2 24 | $706.4M | $362.1M | ||
| Q1 24 | $646.7M | $382.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.50× | ||
| Q3 24 | — | 1.82× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $-5.8M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $-7.8M |
| 自由现金流率自由现金流/营收 | 29.4% | -5.5% |
| 资本支出强度资本支出/营收 | 0.0% | 1.4% |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | $-41.9M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $-5.8M | ||
| Q3 25 | $32.4M | $-968.0K | ||
| Q2 25 | $71.3M | $-4.0M | ||
| Q1 25 | $60.0M | $-23.1M | ||
| Q4 24 | $70.9M | $6.8M | ||
| Q3 24 | $72.9M | $1.1M | ||
| Q2 24 | $64.1M | $-8.9M | ||
| Q1 24 | $31.9M | $-16.8M |
| Q4 25 | $44.9M | $-7.8M | ||
| Q3 25 | — | $-1.8M | ||
| Q2 25 | $71.3M | $-7.0M | ||
| Q1 25 | — | $-25.3M | ||
| Q4 24 | $70.8M | $5.7M | ||
| Q3 24 | $72.6M | $101.0K | ||
| Q2 24 | $64.1M | $-11.0M | ||
| Q1 24 | $31.7M | $-19.9M |
| Q4 25 | 29.4% | -5.5% | ||
| Q3 25 | — | -1.5% | ||
| Q2 25 | 48.6% | -6.6% | ||
| Q1 25 | — | -24.3% | ||
| Q4 24 | 49.9% | 4.4% | ||
| Q3 24 | 56.4% | 0.1% | ||
| Q2 24 | 52.3% | -9.2% | ||
| Q1 24 | 32.2% | -16.5% |
| Q4 25 | 0.0% | 1.4% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 2.8% | ||
| Q1 25 | 0.0% | 2.2% | ||
| Q4 24 | 0.1% | 0.8% | ||
| Q3 24 | 0.2% | 0.9% | ||
| Q2 24 | 0.0% | 1.7% | ||
| Q1 24 | 0.2% | 2.5% |
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.57× | -330.22× | ||
| Q1 24 | 1.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
